On Demand 2016 Practical Advice for the Diagnosis/Management of Drug Allergy (MOC)

You can earn up to 1.5 AMA PRA Category 1 Credit(s). This activity has also been designated by the ABAI for 1.5 MOC Part II Self-Assessment credits. 

The majority of patients reporting penicillin allergy are not truly allergic. Avoidance of penicillin/beta-lactam antibiotics leads to using broader-spectrum, more expensive antibiotics. Rapid desensitization pursued unnecessarily also results in higher costs. This session will allow participants to optimize evaluations of patients reporting drug allergies, leading to improved, cost-effective care.

Release Date: 12/01/2016

Expiration Date: 11/30/2019

Accreditation

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Learning Objectives

  • Optimize the evaluation of a patient reporting a drug allergy using a focused history
  • Discuss cost effective methods for using skin testing and drug challenge to evaluate patients reporting a drug allergy
  • Understand when cephalosporins can be used safely despite a history of PCN allergy
Additional information
Disclosure: 
  • David A. Khan, MD, FACAAI, Moderator -- Speaker: Genentech
  • Aleena Banerji, MD – Nothing to disclose
  • Eric M. Macy, MD – Supported/Contracted Research: ALK
  • Roland Solensky, MD, FACAAI – Nothing to disclose

This activity is supported by independent educational grants from the following commercial supporters:

AstraZeneca Partial support of Workshop W24 on Managing Severe Asthma in Adults and Children.

Boston Scientific Supporter of the Virtual Roundtable on Advancing Management of Severe Asthma: A Review of Available Evidence to Guide Current Treatment.

CSL Behring Supporter of the Friday Symposium on Diagnosis and Treatment of Primary Immune Deficiency.

Dormer Laboratories Inc. In-kind support consisting of loaned durable equipment for Workshop W6 on Office Procedures for Allergic Skin Diseases.

GlaxoSmithKline Supporter of the Sunday Symposium on What to Do When Asthma Does Not Respond to Step 3 Treatment…and partial support of Workshop W24 on Managing Severe Asthma in Adults and Children.

Karl Storz Endoscopy-America, Inc. In-kind support consisting of loaned durable equipment for Workshops W12, W15 and W17 – Hands-On Session in Rhinolaryngoscopy.

Meda Pharmaceuticals, Inc. Supporter of the Monday Plenary Session on Asthma in 2016: Advances in Understanding Origin, Presentation and Approaches to Management.

Micro Direct, Inc. In-kind support consisting of loaned durable equipment for Workshops AHP3 and AHP6 Nuts and Bolts of Spirometry Interpretation.

Mylan Specialty L.P. Supporter of the Friday Breakfast Symposium on Leading the Pack: Allergists as Anaphylaxis Experts.

Nestlé Nutrition Institute Supporter of Workshop W11 on Food Allergies: What’s New in Prevention and Treatment.

Regeneron Pharmaceuticals/ Sanofi Genzyme Partial support of the Monday Plenary Session on Modern Therapies for Allergic Skin Diseases.

Salix Pharmaceuticals Partial support of the Friday Luncheon Symposium on Early Recognition and Effective Management of Hereditary Angioedema…and a video session of the symposium.

Shire Partial support of the Friday Luncheon Symposium on Early Recognition and Effective Management of Hereditary Angioedema…and the Sunday Symposium on Immunoglobulin Replacement for the Allergist: Update on Guidelines.

SmartPractice In-kind support consisting of loaned durable equipment for Workshop W6 on Office Procedures for Allergic Skin Diseases.

Teva Respiratory Supporter of the Friday Symposium on The Use of Biologics in Severe Asthma.

Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Attendance
  • 1.50 MOC
Course opens: 
12/01/2016
Course expires: 
11/30/2019
Cost:
$36.00
Rating: 
0

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Attendance
  • 1.50 MOC

Accreditation Period

Course opens: 
12/01/2016
Course expires: 
11/30/2019

Price

Cost:
$36.00
Please login or create an account to take this course.